Soma Sengupta, Chair and Neurologist-in-Chief at Tufts Medicine, shared on LinkedIn:
“On my way to the Philadelphia Convention Center, I came across Benjamin Franklin’s statue – a fitting prelude to a day exploring electricity, neural signaling, and cancer at the Society for Integrative Oncology Conference.
Yesterday and today, there were four hours of cancer neuroscience talks planned by Steven Brem, myself, Matt Dun, Yuan Pan, weaving together fascinating work by trainees.
- Steven Brem talked about the vagus nerve stimulation in glioblastoma,
- Matt Dunn on diffuse midline glioma,
- Yuan Pan on optic nerve glioma,
- and myself on GABA-A receptors in cancer.
Thank you to Tara Mammoser and the SNO 2026 team for all their incredible work in making the conference a success.
The conversations continued over a wonderful lunch with Josh Neman, a visit to the puppies at the SNO wellness space, and time with Maria G. Castro.
The day ended around the dinner table, with an amazing meal cooked by my dear friend Dolores Hambardzumyan, alongside Maria, Steven Rosenfeld, Craig Horbinski, and others.
‘Science brings us together, friendship makes these gatherings especially meaningful.’
Grateful for a day full of ideas, warmth, and connection.”

About SNO 2026
The 31st Annual Meeting and Education Day of the Society for Neuro-Oncology (SNO 2026) took place from November 12 to 15, 2026, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
Under the theme ‘Crossing the Translational Divide: From Neurons to Novel Therapies,’ the congress brought together more than 3,000 researchers and clinician-scientists from over 40 countries to explore advances across multidisciplinary neuro-oncology research, diagnosis, and treatment.
The comprehensive program featured cutting-edge scientific and poster sessions, expert-led presentations, exhibits, networking activities.
The 2026 SNO Education Day on November 12 gathered international thought leaders to highlight advances in brain tumor treatment. Sessions featured emerging diagnostics, AI, biomarkers, targeted therapies, cell-based immunotherapies, and novel CNS drug-delivery platforms – with a focus on obstacles and clinical translation.
You can also read: Presenting New Neuro-Oncology Data Across 9 Presentations at SNO 2026 – Servier Pharmaceuticals